The role of blood and blood products in acquisition of cytomegalovirus (CMV) infections following transfusion was reviewed in this study. CMV IgG prevalence was particularly high in Bangladesh. Thus 97% of the study groups were found to be CMV IgG positive. The present study showed that CMV IgM antibody prevalence was significantly higher in multiple transfused groups (24%) than control group (2%) indicating CMV primary infection and reactivation or reinfection occur frequently in multitransfused patients. Most CMV infections acquired after transfusion are either asymptomatic or characterized by a self-limited infectious mononucleosis syndrome but it may be serious or fatal in those who are immunocompromised. Particularly at risk are low-birth weight infants, bone marrow and organ transplant patients. If a patient is at high risk of getting CMV diseases, blood from seronegative donors is appropriate and likely to prevent post transfusion CMV infection. Alternatively, blood that has been filtered to decrease the number of white blood cells - the cells that carry CMV - will protect patients from getting a CMV infection from transfusion.DOI: http://dx.doi.org/10.3329/bjmm.v4i2.10828
Life-threatening coagulopathy associated with acute promyelocytic leukemia (APL) has been the defining clinical characteristic and is an important risk factor for fatal haemorrhage and early death. Pathogenesis of coagulopathy in APL is complex and mainly includes disseminated intravascular coagulation (DIC). The study was done to see the status of DIC and its impact on the outcome of APL in our setting. Among the total 60 patients, induction mortality rate was 30% and remission rate was 70%. The main cause of induction mortality was bleeding that accounts for 66.7% of mortality. DIC was present among 32 out of 60 patients (53.33%). Induction mortality has significant relationship to DIC as the induction mortality rate is 47% in patients with DIC and 11% in patient without DIC (P value 0.0009 ). Induction motality rate in low, intermediate and high risk group is 6.7%, 24% and 58% respectively (p value <0.0001). Finally, risk group subclassification revealed presence of DIC in high risk group has the highest early mortality rate
Chronic tonsillitis is a common disease found worldwide mostly in school going children. There are many challenges in the management of chronic tonsillitis especially in refractory cases. There are many single as well compound drugs for the management of tonsillitis which are being used for a longer duration without any known side effect. A randomized open comparative study was designed to validate the efficacy of two very commonly prescribed formulations in the patients of chronic tonsillitis viz. Laooq Sapistan Khyar Shambari and Sharbat Toot Siyah.
Laooq Sapistan Khyar Shambari 6 gm and Sharbat Toot Siyah 20 ml were given orally twice a day to the patients of Group A & Group B respectively for 6 weeks continuously. The data was compiled and statistically analyzed using chi square test and paired t-test.
In test group A, maximum benefit was seen in Sore throat (p<0.0001, χ2 =48.81), followed by Irritation in throat (p<0.0001, χ2 =17.23), Pain in throat (p<0.0001, χ2 =17.23), dry cough (p=0.0002, χ2 =14.35) and dysphagia (p=0.0076, χ2 =7.12). In test group B, maximum benefit was observed in sore throat (p=0.0076, χ2 =7.12), followed by notable improvement in irritation in throat (p=0.0014, χ2 =10.15), and pain in throat (p=0.0098, χ2 =6.67).
Although both Laooq Sapistan Khyar Shambari and Sharbat Toot Siyah are effective, but Laooq Sapistan Khyar Shambari is a better option for the management of chronic tonsillitis; as it relives most of the symptoms & signs very effectively and safely.
Keywords: Chronic tonsillitis, Unani formulation, Laooq Sapistan Khyar Shambari, Sharbat Toot Siyah
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.